The latest market report published by Credence Research, Inc. “Global Needle Free Diabetes Management Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022,” the needle free diabetes management market was valued at USD 3,225.6 Mn in 2015, and is expected to reach USD 9,797.8 Mn by 2022, expanding at a CAGR of 16.8% from 2016 to 2022.
Diabetes is majorly classified into Type 1 diabetes (due to b-cell destruction, usually leading to absolute insulin deficiency), Type 2 diabetes (due to a progressive loss of insulin secretion on the background of insulin resistance) and gestational diabetes mellitus (GDM) (diabetes diagnosed in the second or third trimester of pregnancy that is not clearly overt diabetes).
Browse the full report Needle Free Diabetes Management Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2022 at http://www.credenceresearch.com/report/needle-free-diabetes-management-market
According to the International Diabetes Federation, in 2015 about 415 million people were observed suffering with diabetes and by 2040 the number is expected to soar to 642 million worldwide. In 2015, North America and Caribbean comprised patient population of 44.3 million, Europe possessed 59.8 million, South East Asia had 78.3 million, Western Pacific had 153.2 million, South & Central America had 29.6 million, and Africa had 14.2 million.
The market segmentation of needle free diabetes management market is carried out on the basis of type of devices and geography. The devices segment is further sub-segmented into treatment devices, diagnostic devices and artificial pancreas. Treatment devices comprise of insulin pens, pumps & patches, inhalers and jet injectors. Insulin patch & pump was observed as the fastest growing segment in treatment devices segment due to high efficiency, patient convenience, and rising public awareness related to the novel needle-free treatment devices. Insulin pens and jet injectors collectively accounted for the largest market share of around 51% of the overall needle-free diabetes treatment market as they are one of the most initial treatment solutions available in the market, high market penetration achieved till date and high public awareness related with the products. Geography segmentation comprised regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. North America was observed as the largest and most potential regional market for needle free diabetes management market. North America constitutes regional markets of U.S. and Canada, the rising prevalence of diabetes is the major driver for the growth of North America needle free diabetes management market. The developed healthcare infrastructure, high public awareness related to diabetes management, and rising research and development activities related to diabetes management are the key factors assisting the growth of North America needle free diabetes management market.
Request Sample: http://www.credenceresearch.com/sample-request/58012
Market Competition Assessment:
The needle free diabetes management market is observed as the most diversified and competitive market comprising large number of players. The market is dominated by several players, depending on their major competencies. The key players in this market are Zogenix, Inc., 3M, Antares Pharma Inc., Glide Pharmaceutical Technologies Ltd., Injex Pharma AG, Pharmajet, Inc., Bioject Medical Technologies, Inc., Medtronic, Inc., Johnson & Johnson, Inc., Pancreum LLC, Tandem Diabetes Care, Inc., JDRF, and Akra Dermojet.
Key Market Movements:
- Rising prevalence of diabetes worldwide as is claimed as one of the most chronic diseases if not well managed and is expected to reach alarming levels in the coming years
- The technology to manage diabetes is developing at significant pace some ground breaking innovations in the field of artificial pancreas are considered to change the needle free diabetes management market
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
What we do
We serve customers at each level of their organization, in whatever limit we can be most helpful, whether as a trusted counsel to top management or as a hands-on mentor for forefront representatives. For each engagement, we collect a group with the most suitable experience and ability.
No matter the challenge, we concentrate on delivering functional and persevering results, and preparing our customers to develop and lead. We join forces with customers to place suggestions into practice. Our research specialist work straightforwardly with customers over long stretches to create workforce aptitudes, drive operational change, and apply new working strategies.
Name: Chris Smith
Designation: Global Sales Manager